bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test

The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive lung cancer detection technology, expanding the company’s intellectual property coverage in Asia. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) has received a Japanese patent allowance covering its CyPath Lung diagnostic method and AI-built algorithm.